At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PET Wag! Group Co
Post-Market Trading 03-24 16:20:57 EDT
0.1960
-0.0503
-20.42%
盘后0.2000
+0.0040+2.04%
16:13 EDT
| High0.2500 | Low0.1810 | Vol1.47M |
| Open0.2500 | D1 Closing0.2463 | Amplitude28.01% |
| Mkt Cap9.76M | Tradable Cap4.14M | Total Shares49.79M |
| T/O296.18K | T/O Rate6.95% | Tradable Shares21.12M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Top Midday Decliners
MT Newswires Live · 18:37
Wag! Group Co reports results for the quarter ended December 31 - Earnings Summary
Reuters · 13:31
Wag! Group 2025 Outlook: Expects Revenues Of $84M-$88M Vs. $75.30M Est., Sees Adjusted EBITDA Of $2M-$4M
Benzinga · 11:04
Wag Group Q4 2024 GAAP EPS $(0.10) Misses $(0.05) Estimate, Sales $15.43M Miss $18.90M Estimate
Benzinga · 11:01
Wag! Group Co: Q4 Loss per Share $0.10
THOMSON REUTERS · 11:00
Wag! Group Q4 Revenue USD 15.4 Million
THOMSON REUTERS · 11:00
Wag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value
THOMSON REUTERS · 11:00
Press Release: Wag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value
Dow Jones · 11:00
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
Stockheads · 02:33
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
Wag! Group Co expected to post a loss of 5 cents a share - Earnings Preview
Reuters · 03-21
Wag! To Report Fourth Quarter and Full Year 2024 Financial Results on March 24, 2025
GlobeNewswire · 03-18
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
GlobeNewswire · 03-17
Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
Dow Jones · 03-13
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
GlobeNewswire · 03-11
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
GlobeNewswire · 03-11
Loop Announces Senior Leadership Appointments and Changes
ACCESS Newswire · 03-07
Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
Dow Jones · 03-06
CIBC Reaffirms Their Buy Rating on Pet Valu Holdings Ltd. (PET)
TIPRANKS · 03-05
Pet Valu Holdings Ltd. (PET) Gets a Buy from Barclays
TIPRANKS · 03-05
Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment
MT Newswires Live · 03-03
Introduction
Company Name.
Wag! Group Co
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App